Cited 0 times in Scipus Cited Count

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement

DC Field Value Language
dc.contributor.authorChin, SO-
dc.contributor.authorKu, CR-
dc.contributor.authorKim, BJ-
dc.contributor.authorKim, SW-
dc.contributor.authorPark, KH-
dc.contributor.authorSong, KH-
dc.contributor.authorOh, S-
dc.contributor.authorYoon, HK-
dc.contributor.authorLee, EJ-
dc.contributor.authorLee, JM-
dc.contributor.authorLim, JS-
dc.contributor.authorKim, JH-
dc.contributor.authorKim, KJ-
dc.contributor.authorJin, HY-
dc.contributor.authorKim, DJ-
dc.contributor.authorLee, KA-
dc.contributor.authorMoon, SS-
dc.contributor.authorLim, DJ-
dc.contributor.authorShin, DY-
dc.contributor.authorKim, SH-
dc.contributor.authorKwon, MJ-
dc.contributor.authorKim, HY-
dc.contributor.authorKim, JH-
dc.contributor.authorKim, DS-
dc.contributor.authorKim, CH-
dc.date.accessioned2020-10-21T07:21:21Z-
dc.date.available2020-10-21T07:21:21Z-
dc.date.issued2019-
dc.identifier.issn2093-596X-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/18908-
dc.description.abstractThe Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.-
dc.language.isoen-
dc.subject.MESHAcromegaly-
dc.subject.MESHAntineoplastic Agents-
dc.subject.MESHAntineoplastic Agents, Hormonal-
dc.subject.MESHAttitude-
dc.subject.MESHConsensus-
dc.subject.MESHDecision Making-
dc.subject.MESHExpert Testimony-
dc.subject.MESHHumans-
dc.subject.MESHInjections, Intramuscular-
dc.subject.MESHInsurance, Health-
dc.subject.MESHNeuroendocrinology-
dc.subject.MESHOctreotide-
dc.subject.MESHPeptides, Cyclic-
dc.subject.MESHPractice Guidelines as Topic-
dc.subject.MESHPreoperative Period-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHSomatostatin-
dc.titleMedical Treatment with Somatostatin Analogues in Acromegaly: Position Statement-
dc.typeArticle-
dc.identifier.pmid30912339-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435847/-
dc.subject.keywordAcromegaly-
dc.subject.keywordLanreotide-
dc.subject.keywordOctreotide-
dc.subject.keywordPasireotide-
dc.subject.keywordSomatostatin analogues-
dc.contributor.affiliatedAuthor김, 대중-
dc.type.localJournal Papers-
dc.identifier.doi10.3803/EnM.2019.34.1.53-
dc.citation.titleEndocrinology and metabolism (Seoul, Korea)-
dc.citation.volume34-
dc.citation.number1-
dc.citation.date2019-
dc.citation.startPage53-
dc.citation.endPage62-
dc.identifier.bibliographicCitationEndocrinology and metabolism (Seoul, Korea), 34(1). : 53-62, 2019-
dc.identifier.eissn2093-5978-
dc.relation.journalidJ02093596X-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
Files in This Item:
30912339.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse